Skip to main content

Day: December 19, 2024

Rezolve Ai Announces Pricing of $15 Million Registered Offering

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) — Rezolve Ai (NASDAQ: RZLV) (the “Company), a global leader in AI-driven retail innovation, today announced that it has entered into definitive agreements for the purchase and sale of 5,000,000 of the Company’s ordinary shares (or pre-funded warrants in lieu thereof) and warrants to purchase up to 5,000,000 ordinary shares at a purchase price of $3.00 per share (or per pre-funded warrant in lieu thereof) and accompanying warrant in a registered offering. The warrants will have an exercise price of $3.00 per share, will be exercisable immediately upon issuance and will expire on the earlier of (i) thirty days after the volume weighted average price of the ordinary shares is at or above $6.00 for five consecutive trading days and (ii) five years from the date of issuance. The closing of the...

Continue reading

Greenridge Exploration Closes Flow Through Private Placement Financing & Enters Into Marketing Agreement Engagement

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) — Greenridge Exploration Inc. (“Greenridge” or the “Company”) (CSE: GXP | FRA: HW3), announces that further to its December 3, 2024 news release, the Company has closed its non-brokered private placement of flow-through units (each, a “FT Unit“) for aggregate gross proceeds in this second tranche of $4,947,433.92 (the “Offering“). The Company has issued 5,622,084 FT Units at a price of $0.88 per FT Unit, with each FT Unit comprised of one (1) common share of the Company (each, a “Common Share”) issued on a flow-through basis under the Income Tax Act (Canada) (each, a “FT Share”) and one half of one Common Share purchase warrant (each whole...

Continue reading

Aura Announces Bluestone Securityholders’ Approval of Transaction

ROAD TOWN, British Virgin Islands, Dec. 19, 2024 (GLOBE NEWSWIRE) — Aura Minerals Inc. (TSX: ORA, B3: AURA33) (“Aura” or the “Company”), following our press releases dated October 28, 2024, and November 5, 2024, is pleased to announce that the securityholders of Bluestone Resources Inc. (“Bluestone”) have approved the previously announced acquisition of Bluestone by Aura by way of a plan of arrangement (the “Transaction” or the “Arrangement”) at a special meeting of Bluestone Securityholders held earlier today. The special resolution approving the Transaction was approved by (i) 99.48% of the votes cast by Bluestone’s shareholders present or represented by proxy at the Meeting; (ii) 99.54% of the votes cast by Bluestone Shareholders and optionholders, voting together as a single class, present or represented by proxy at the Meeting;...

Continue reading

Zefiro Methane Corp. 2024 Year in Review: Accelerating Commercial Growth and Operational Impact

The Company achieved numerous commercial milestones in 2024, including increased profitability, launching an initial public offering, moving into new marketplaces, securing key strategic acquisitions and partnerships, and finalizing landmark carbon offset presales FORT LAUDERDALE, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) — ZEFIRO METHANE CORP. (Cboe Canada: ZEFI) (Frankfurt: Y6B) (OTCQB: ZEFIF) (the “Company”, “Zefiro”, or “ZEFI”), an environmental services company specializing in methane abatement operations, took numerous steps in 2024 to accelerate the Company’s profitability and commercial momentum. Specifically, Zefiro’s success over the past twelve months can be attributed to its execution of the Company’s strategy to expand its commercial footprint in critical marketplaces across North America and generate industry-leading,...

Continue reading

BlackRock® Canada Postpones Unitholder Meeting of iShares Premium Money Market ETF to Approve Investment Objective Change

Listing:         TSX (Toronto Stock Exchange) Symbol:         CMR TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) — BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (“BlackRock”) (NYSE: BLK) announced on November 8, 2024, that it called a special meeting of unitholders (the “Meeting”) of the iShares Premium Money Market ETF (the “iShares Fund”), to originally be held on or about January 22, 2025 to approve a change to the investment objective of the iShares Fund to permit investments in asset-backed commercial paper (the “Proposal”). As a result of the Canada Post labour disruption, BlackRock Canada is postponing the Meeting to February 3, 2025. BlackRock Canada is holding the Meeting solely as a virtual (online) meeting by way of live audio webcast.   In accordance...

Continue reading

VivoPower completes filing of 2024 Annual Report on Form 20-F

Filing follows successful completion of the independent audit for the year ended 30 June 2024 Prior non-compliance with NASDAQ listing requirements due to delayed filing has been remedied LONDON, Dec. 19, 2024 (GLOBE NEWSWIRE) — On December 19, 2024, VivoPower International PLC (Nasdaq: VVPR) (“VivoPower” or the “Company”) filed its 2024 Annual Report on Form 20-F. This follows the successful completion of the independent audit for the year ended 30 June 2024. As a result of this filing, the Company has rectified a prior non-compliance with listing requirements of the Nasdaq Stock Market (“Nasdaq”), including Listing Rule 5250(c)(1). The delay in the filing of the Form 20-F was due to the number of significant strategic changes to the Company, including the divestiture of business units. About...

Continue reading

Silvaco Announces that The Ninth Circuit affirmed the dismissal of all claims against Silvaco brought by Aldini AG

SANTA CLARA, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) — Silvaco Group, Inc. (Nasdaq: SVCO) (“Silvaco”), a provider of TCAD, EDA software and SIP solutions that enable semiconductor design and digital twin modeling through AI software and innovation, today announced that the U.S. Court of Appeals for the Ninth Circuit affirmed the U.S. District Court for the Northern District of California’s dismissal of all claims against Silvaco brought by Aldini AG. “We are pleased with the court’s decision,” said Babak Taheri, CEO of Silvaco. “This outcome validates our commitment to integrity. With this matter resolved, we can dedicate our full attention to what truly matters: empowering our customers and driving innovation in the industry.” About Silvaco Silvaco is a provider of TCAD, EDA software and...

Continue reading

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, today announced the acquisition of patent number WO 2023/086647 PCT/US2022/049857, for mushroom-derived compositions and methods of treatment. This new addition to MangoRx’s intellectual property portfolio highlights the Company’s commitment to innovative solutions that support holistic health and wellness. The acquired patent encompasses nutraceutical compositions derived from functional mushrooms, including well-known varieties such as Cordyceps sinensis, Ganoderma lucidum (Reishi), and Hericium erinaceus (Lion’s Mane). These formulations are designed to deliver a range of health benefits, such...

Continue reading

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that Express Scripts, the pharmacy benefits business of Evernorth Health Services, has added neffy® (epinephrine nasal spray) to its Commercial national formularies. This decision makes neffy broadly available to millions of their commercially insured patients across the country. neffy 2 mg is for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh...

Continue reading

Par Pacific Announces 2025 Capital Expenditure Guidance

HOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) — Par Pacific Holdings, Inc. (NYSE: PARR) (“Par Pacific”) today announced its 2025 capital expenditure and turnaround outlay guidance with a range of $210 million to $240 million.  2025 Capital Expenditure and Turnaround Outlay Guidance$ in millions     Turnarounds & Catalyst $85 – 95Maintenance 1 75 – 85Growth 2 50 – 60Total Capital Expenditure and Turnaround Outlay $210 – 240Includes approximately $10 million in reliability investments. Includes approximately $30-40 million to complete the Hawaii renewable hydrotreater project and $10 million in ERP system enhancements.Management expects 2024 capital expenditures and turnaround outlays to come in at the low end of the $220 million to $250 million guidance range. About Par Pacific Par...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.